Osteopore (ASX:OSX) secured Malaysian regulatory access for its orthopaedic portfolio, opening a US$250-300m bone graft market with a halal-friendly biomaterials angle.
Healthcare Stocks
AVITA Medical (ASX:AVH) Q1 2026 revenue rose 10% sequentially to US$19.3m but cash fell to US$14.3m as a new CEO and BARDA deal reset the story.
It is hard to look back on something and say it failed especially if it was a US$11.7bn bet as CSL's Vifor acquisition was. But what else can you say? Impairments now total roughly US$6.5bn, the share price is barely over $100 having peaked at over $300 only a couple of years ago and the…
CSL Hits Decade Lows: Buy the Dip or Wait?
CSL (ASX:CSL) shares slipped another 2% today, extending yesterday's brutal sell-off that pushed the stock to its lowest level since 2017. The biotech heavyweight is now down around 44% for the year, a fall few investors would have thought possible for what was long considered one…
BPH Global (ASX:BP8) has signed a Singapore Polytechnic FIRC agreement to develop powdered seaweed kefir, signalling a pivot to a functional ingredients model.
dorsaVi (ASX:DVL) has renewed its US DoD-funded research contract with Georgia Southern University, framing the study as a proving ground for exoskeletons.
CSL Limited (ASX:CSL) has cut FY26 guidance and flagged US$5 billion in non-cash impairments including CSL Vifor, as the interim CEO resets the story.
Amplia (ASX:ATX) Adds Ovarian Trial with ANZGOG After Narmafotinib Hits 35% Pancreatic Response Rate
Amplia Adds Ovarian Trial After Pancreatic Success
Amplia Therapeutics (ASX:ATX) has opened a new chapter in its drug story. On 8 May, the small-cap biotech announced a partnership with the Australia New Zealand Gynaecological Oncology Group (ANZGOG) to test its lead drug, narmafotinib, in ovarian cancer. The new study, called PRROSE, will treat patients with…
ASX Healthcare Stocks Caught in the GLP-1 Storm After Eli Lilly's Blockbuster Quarter
Eli Lilly (NYSE:LLY) just delivered a knockout first-quarter 2026 result on Thursday, with sales of its weight-loss drug Mounjaro more than doubling and shares jumping 6% on the day. For ASX investors who still think the GLP-1 weight-loss boom is only a…
ImpediMed (ASX:IPD) raised A$15.2m and cut costs as it works toward FY28 operating cash flow breakeven through SOZO growth.
